MARKET

NUVL

NUVL

Nuvalent, Inc.
NASDAQ
123.25
-0.20
-0.16%
After Hours: 123.22 -0.03 -0.02% 19:54 06/12 EDT
OPEN
123.36
PREV CLOSE
123.45
HIGH
123.45
LOW
123.16
VOLUME
7.24M
TURNOVER
--
52 WEEK HIGH
123.62
52 WEEK LOW
71.13
MARKET CAP
9.75B
P/E (TTM)
-20.3618
1D
5D
1M
3M
1Y
5Y
1D
Weekly Buzz: GH, LLY Gain FDA Nod; TEVA, GSK, Lead M&A Wave; ZEAL, LLY Post Strong Data
NASDAQ · 23h ago
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
Benzinga · 1d ago
3 Best Trending Stocks, According to Analysts – 6/11/2026
TipRanks · 1d ago
Nuvalent Chief Development Officer Darlene Noci sells 20,000 shares for $2.46 million
PUBT · 1d ago
Nuvalent: 'Hold' On GlaxoSmithKline Acquisition For Selective Tyrosine Kinase Inhibitors
Seeking Alpha · 1d ago
Analysts Offer Insights on Healthcare Companies: Alterity Therapeutics (OtherPRNAD) and Nuvalent (NUVL)
TipRanks · 2d ago
Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal
Reuters · 2d ago
Nuvalent CEO James Richard Porter disposes of common shares worth $2,660,308.96
PUBT · 2d ago
More
About NUVL
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, and address brain metastases. It is advancing a robust pipeline with investigational candidates for ROS proto-oncogene 1 (ROS1)-positive, anaplastic lymphoma kinase (ALK)-positive, and human epidermal growth factor receptor 2 (HER2)-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, Zidesamtinib (NVL-520), is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, Neladalkib (NVL-655), is being developed for patients with ALK-positive NSCLC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant HER2-selective inhibitor.

Webull offers Nuvalent, Inc stock information, including NASDAQ: NUVL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NUVL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NUVL stock methods without spending real money on the virtual paper trading platform.